Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: DPPE; YMB-1002

Latest Information Update: 11 Mar 2014

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CancerCare Manitoba; University of Manitoba
  • Developer Shin Poong Pharmaceutical; YM BioSciences
  • Class Antineoplastics; Phenyl ethers; Small molecules
  • Mechanism of Action Estrogen receptor antagonists; Histamine receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Gastric cancer; Prostate cancer

Most Recent Events

  • 02 Feb 2007 YM BioSciences terminates a worldwide pivotal phase III trial (DEC) in advanced Breast cancer
  • 21 Dec 2006 YM Biosciences and TTY Biopharm agree to co-develop tesmilifene for Liver cancer in Taiwan
  • 05 Jun 2006 Phase-II clinical trials in combination with docetaxel in patients with metastatic Breast Cancer in Europe and USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top